We are a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Our robust pipeline includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE), as well as wet age-related macular degeneration (wAMD).

Leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. We are well positioned with core capabilities, which include clinical development and in-house manufacturing expertise, specifically in process development and assay development.

Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients with rare and ocular diseases.